Tasigna
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.tasignalawsuit.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Tasigna
Tasigna (nilotinib) is approved in more than 130 countries for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in chronic phase and with chronic and accelerated phase Ph+ CML resistant or intolerant to at least one prior therapy, including Glivec® (imatinib). Tasigna is also approved for the treatment of pediatric patients with newly diagnosed Ph+ CML in the chronic phase and with resistance or intolerance to prior TKI therapy.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tasigna your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Tasigna recently announced quarterly report
Check out if Tasigna is spiking on competitors!
Product Launch: Get notified when Tasigna launches new products
Check if Tasigna has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Tasigna
Funding: Get notified immidiatlly once Tasigna has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Tasigna had a recent Job posting/layoffs
Tasigna, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Tasigna
Find 3 more new buyers
Compare Similar Companies to Tasigna
Compare insights from companies similar to Tasigna, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Tasigna
<$5M
11-50
Private
-
-
N/A
$13.7M
1-10
Private
<$5M
2000
KC
Kirstie CarterOffice Manager, Mass Tort Case Coordinator and Personal Legal Assistant To Noble McIntyre
Company Profile Activity
Activity Insights
Tasigna is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tasigna is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tasigna.
Tasigna Tech Stack
A closer look at the technologies used by Tasigna
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Tasigna
Sign Up For FreeTo access detailed company insights
Tasigna (nilotinib) is approved in more than 130 countries for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in chronic phase and with chronic and accelerated phase Ph+ CML resistant or intolerant to at least one prior therapy, including Glivec® (imatinib). Tasigna is al... Read More
